Numerous small molecule drugs have therefore been developed that aim to reduce HSF1 activity, although most agents have not been shown to directly interact with HSF1 and have yet to show sufficient preclinical potential to enter the cancer clinic [48,196]. The gene discussed is HSF1; the disease is cancer.